A Phase 2 interventional study of SHR-A1811 and SHR-1701 and SHR-A1811 and capecitabine in HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 5 under way, 2 of them phase 3. Stomach Neoplasms · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 4 in phase 2, and was the 11th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →5 of the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–70
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 5
First in 2011; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 151 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Suzhou Suncadia Biopharmaceuticals Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
1 of the studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06123494Phase 3Jiangsu HengRui Medicine Co., Ltd.SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2 expression advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients.
The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2 expression gastric/gastroesophageal conjunctional adenocarcinoma patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-A1811 and SHR-1701
Drug: SHR-A1811 and capecitabine
Drug: SHR-A181, SHR-1701, and capecitabine
Drug: SHR-A1811, SHR-1316, and capecitabine
Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
Drug: SHR-A1811, SHR-1316, and 5-FU
Drug: SHR-A1811, SHR-1316, and capecitabine
Drug: SHR-1316 and SHR-A1811
Drug: SHR-A1811 and capecitabine
Drug: SHR-A1811, SHR-1316, and 5-FU
Drug: SHR-A1811and 5-FU
Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
Drug pages: Trastuzumab rezetecan · SHR-1701
(Arm 1A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion;
Drug pages: Trastuzumab rezetecan · Capecitabine
(Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug:capecitabine, administered orally;
(Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug:capecitabine, administered orally;
(Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally;
(Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally; Drug:oxaliplatin,administered as an IV infusion
(Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:5-FU,administered as an IV infusion
(Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug:capecitabine, administered orally;
Drug pages: Adebrelimab · Trastuzumab rezetecan
(Arm 2B) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion
Drug pages: Trastuzumab rezetecan · Capecitabine
(Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug:capecitabine, administered orally;
(Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:5-FU,administered as an IV infusion
(Arm 2E) Drug: SHR-A1811, administered as an IV infusion Drug:5-FU,administered as an IV infusion
(Arm 2F) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally; Drug:oxaliplatin,administered as an IV infusion
Phase Ib: Dose limiting toxicity (DLT) rates, Occurrence of adverse events (AEs), and serious adverse events (SAEs)
Time frame: Safety will be assessed for approximately 24 months from informed consent
Phase II: Objective Response Rate (ORR)[
Time frame: An average of approximately 12 months
ORR(Phase Ib)
Time frame: An average of approximately 12 months
DoR(Phase Ib)
Time frame: An average of approximately 18 months
PFS(Phase Ib)
Time frame: An average of approximately 18 months
OS(Phase Ib)
Time frame: An average of approximately 30 months
DoR(Phase II)
Time frame: An average of approximately 18 months
PFS(Phase II)
Time frame: An average of approximately 18 months
OS(Phase II)
Time frame: An average of approximately 30 months
Occurrence of adverse events (AEs), and serious adverse events (SAEs) (Phase II)
Time frame: Safety will be assessed for approximately 24 months from informed consent]
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 57 months is above that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab rezetecan · SHR-1701 · Capecitabine · Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd. →